Uncategorized

Byetta Sales Accelerating

As Diabetic Investor predicted sales of Byetta are accelerating as physicians see how well the drug works. According to IMS tracking data Byetta has a 1.7% share of the market for Type 2 medications. Not surprisingly shares of Amylin Pharmaceuticals (NASDAQ: AMLN) are once again on the move as the Street begins to take notice. With shares trading within an eyelash of its 52 week high the question becomes...

Lilly/Alkermes Release Data on inhaled insulin – What are these people thinking?

This morning Lilly (NYSE:LLY) and Alkermes (NASDAQ:ALKS) released data from a Phase 2 clinical study of inhaled insulin in people with type 1 diabetes. Patients achieved an average A1C level of 7.9 using the Lilly/Alkermes system, compared to 8 for the injection group. Unfortunately the American Diabetes Association (ADA) defines good control as patients with an A1C of 7 or below. Amazingly shares of Lilly and Alkermes were up on...

What the Street is missing on Exubera.

A week from tomorrow an FDA panel will meet to discuss Exubera the inhaled form of insulin from Pfizer (NYSE:PFE), Sanofi-Aventis (NYSE:SNY) and Nektar (NASDAQ:NKTR). Since this will be one of the first panel meetings after the Vioxx verdict and because there is a fascination with any non-injectable form of insulin the panel meeting has gained national attention. For some time Diabetic Investor has reported that even if approved, by...

What the Street is missing on Exubera.

A week from tomorrow an FDA panel will meet to discuss Exubera the inhaled form of insulin from Pfizer (NYSE:PFE), Sanofi-Aventis (NYSE:SNY) and Nektar (NASDAQ:NKTR). Since this will be one of the first panel meetings after the Vioxx verdict and because there is a fascination with any non-injectable form of insulin the panel meeting has gained national attention. For some time Diabetic Investor has reported that even if approved, by...

Byetta LAR Great Results – What Next?

Yesterday afternoon Amylin Pharmaceuticals (NASDAQ:AMLN) announced results from Phase 2 study for the long acting version of Byetta known as Byetta LAR. The results weren’t good were great. Of the 14 participants in the study 12 achieved an A1C of 7 percent or less at 15 weeks. (A1C is considered the gold standard for measuring control and the American Diabetes Association (ADA) maintains that an A1C of 7% or below...

Byetta LAR Great Results – What Next?

Yesterday afternoon Amylin Pharmaceuticals (NASDAQ:AMLN) announced results from Phase 2 study for the long acting version of Byetta known as Byetta LAR. The results weren’t good were great. Of the 14 participants in the study 12 achieved an A1C of 7 percent or less at 15 weeks. (A1C is considered the gold standard for measuring control and the American Diabetes Association (ADA) maintains that an A1C of 7% or below...

What the Vioxx Verdict Means for Diabetes Drugs

By now everyone has had the opportunity to read something about the $253 million verdict against Merck (NYSE:MRK). While the pundits discuss the ramifications of the verdict on the entire drug industry there are some very real consequences for people with diabetes. In particular what this means for the many drugs under development. Given that FDA is also under scrutiny for the role they played in approving Vioxx, people with...

What the Vioxx Verdict Means for Diabetes Drugs

By now everyone has had the opportunity to read something about the $253 million verdict against Merck (NYSE:MRK). While the pundits discuss the ramifications of the verdict on the entire drug industry there are some very real consequences for people with diabetes. In particular what this means for the many drugs under development. Given that FDA is also under scrutiny for the role they played in approving Vioxx, people with...

Abbott – The Big Bad Wolf

It seems as though the management at Abbott Diabetes Care is so concerned that their Navigator Continuous Blood Glucose Management System won’t be approved by the FDA in the near future that it’s necessary to sue a competitor that doesn’t even have a product in the market. This past Tuesday Abbott (NYSE:ABT) filed a patent infringement action against DexCom (NASDAQ:DXCM). Abbott is basically claiming DexCom stole their idea and...

PolyMedica – Flexing their muscles

This morning PolyMedica (NASDAQ:PLMD) reported their fiscal 2006 first quarter results. As solid as the results were the real news is the management teams’ plans for the future. As regular Diabetic Investor subscribers know, we have been critical of the new management team. Simply put, Diabetic Investor didn’t believe the new team was being aggressive enough. After listening to today’s conference call it seems management has made a complete reversal...